Tianjin Chase Sun Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Tianjin Hongri Pharmaceutical Co., Ltd. (referred to as "Hongri Pharmaceutical") was established in 1996 and was listed on the first national ChiNext board in 2009 (stock code: 300026). It is a state-owned holding enterprise under the State owned Assets Supervision and Administration Commission. The controlling shareholder Chengdu Xingcheng Investment Group Co., Ltd. is a Fortune 500 enterprise, ranking 466th. Hongri Pharmaceutical's business covers six major sectors, including traditional Chinese medicine formula granules, finished drugs, raw and auxiliary materials, medical devices, medical health services, and pharmaceutical intelligent supply chain. It has two national level research and development platforms, namely the National Enterprise Technology Center and the National Local Joint Engineering Research Center for Key Technologies of Traditional Chinese Medicine Formula Granules. It has successively won the titles of National Key High tech Enterprise, National Technological Innovation Demonstration Enterprise, and National Advanced Collective for Poverty Alleviation The National Pioneer Worker and many other honors ranked 41st among the top 100 Chinese pharmaceutical industries and 14th among the top 100 traditional Chinese patent medicines and simple preparations enterprises. In 2022, the main business revenue was 6.65 billion yuan, the total profit was 716 million yuan, and the total assets were 12.631 billion yuan. The traditional Chinese medicine formula particle sector closely revolves around the Kangrentang "full ingredient" traditional Chinese medicine formula particle product line, with 8 intelligent manufacturing production bases in Beijing, Tianjin, Hebei, Henan, Hubei, Gansu, Chongqing, and Shandong. The enterprise strictly controls the core links such as the cultivation of authentic medicinal herbs and the processing according to ancient methods, establishes a full process quality traceability, strictly controls product quality, and maintains a market share at the forefront of the industry. The finished medicine section includes 11 categories, 26 varieties, and 39 product specifications. Among them, Xuebijing Injection is a core product of Hongri Pharmaceutical with independent intellectual property rights. After more than ten years of evidence-based research after its launch, Xuebijing can effectively reduce the mortality rate of severe pneumonia by 8.8%. The relevant paper was published in the top international journal "Critical Care Medicine", and its effectiveness has been recognized by authoritative international experts. In the treatment of COVID-19, Xuebijing was selected into the "three drugs and three parties" of traditional Chinese medicine for anti epidemic and the multi version diagnosis and treatment scheme of COVID-19 was promoted to the world because of its clear clinical efficacy. Under the raw materials sector, there are three companies under the jurisdiction of Outlook Pharmaceuticals, Yinuorui, and Wantai Auxiliary Materials, all of which are leading enterprises in segmented fields, and their products are exported to more than 50 countries and regions. In the medical device sector, there are two companies, Chaosi Electronics and Wenhe Medical Devices. The star product Chaosi Electronic Finger Oximeter was identified as the first batch of key guaranteed products by the state during the fight against the COVID-19. The medical service sector relies on the resources of traditional Chinese medicine experts that have been cooperating for many years, and has opened high-end traditional Chinese medicine chain medical centers in more than 20 cities offline. It has also created traditional Chinese medicine internet hospitals online, with over 50000 registered traditional Chinese medicine students. The pharmaceutical intelligent supply chain sector can provide medical institutions with digital management services throughout the entire process, including procurement, logistics, use, and maintenance. The company has a vision of "inheriting and developing Chinese medicine, solving human health problems", accelerating the organic integration of digital applications with six major business sectors, taking the innovation of the entire industry chain as the "entry point", and continuously practicing the two value propositions of "striving for the people to enjoy high-quality traditional Chinese medicine services!" and "striving for the improvement of China's medical treatment level!", striving to become a leader in Chinese medicine. |
| Headquarter | Tianjin |
| Establish Date | 9/30/2000 |
| Listed Code | 300026.SZ |
| Listed Date | 10/30/2009 |
| Chairman | Yao Xiaoqing. |
| CEO | Zheng Dan. |
| Website | www.chasesun.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
